Manufacturing US puts $125m into personalised RNA therapy production PharmaphorumFederal funding from ARPA-H of $125m, awarded to five groups, is part of a drive to accelerate patient access to personalised genetic medicines.Read full story pharminent September 2, 2026 (Last updated: September 2, 2026) Pharmaphorum Federal funding from ARPA-H of $125m, awarded to five groups, is part of a drive to accelerate patient access to personalised genetic medicines. Read full story Post navigation Previous: Takeda and Weave Bio collaborate on AI-driven automation in drug developmentNext: Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology Related Stories Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026 Manufacturing Roche commits $750m to double Oregon-based US manufacturing capacity pharminent August 21, 2026 Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026